Broad Institute launches collaboration to build gene therapies for rare diseases

A new partnership aims to industrialize gene therapy development for rare conditions that don't attract commercial investment.

The Broad Institute and partners have announced an initiative to develop gene therapies for rare diseases, according to STAT. The aim is to build a shared, repeatable pathway for making these therapies rather than treating each one as a bespoke, one-off effort.

Rare diseases each affect small numbers of people, which means individual treatments rarely justify the cost of standard commercial drug development. An institutional collaboration that spreads the platform work across many conditions could change that math, opening a route to treatments for patients who otherwise have none.

If it works, the approach touches both health and care: it puts therapies within reach for populations the market has skipped, and it may ease the burden on families managing conditions with no options today. This is an early-stage effort, framed as development rather than delivery. The source is a subscriber report we could not access, so the specifics of scope, funding, and timeline sit with STAT's original coverage.

Source: STAT